Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

New spinout enterprise from Oxford seeks to accelerate evidence based innovation for treatments and services in mental health and dementia.

Cristal Health (established in May 2019) has been developed as a sustainable way to accelerate the UK-CRIS programme. The UK-CRIS network operates a managed service for secure access to one of the world's largest repositories of de-identified patient data relating to mental health and dementia conditions.

 

Cristal Health presents a real opportunity for accelerating and translating new discovery medicine, including prevention and treatment, into better health outcomes for sufferers of mental illness and their families. - Mike Dennis, CEO, Cristal Health

Mike Denis, CEO, Cristal Health, said,

"I'm honoured to be leading the team in the joint partnership between the NHS and academia working with industry using real world health data. We're able to add value by continually enriching the clinical content available to clinicians, researchers and scientists which will truly deliver many more opportunities to predict, identify, prevent or manage mental health conditions in the UK." 

The market for real world evidence and data is projected to grow as organisations seek to reduce costs and time, 

 

The spinning out of remarkable new companies like Cristal Health is great news. It brings in investment which allows for exciting initiatives and innovative activity developed in the NHS and Universities to grow more quickly and become sustainable. Everyone benefits and most importantly our patients. - Professor John Geddes, Head of Department of Psychiatry

Cristal Health will focus on three areas:

• Developing offerings to help in early stage drug discovery, reduce clinical trial costs by 12-30%, support post launch and Phase IV evaluation (i.e. following approval) and pharmacovigilance (safety monitoring).

• Supporting NHS Trusts in generating revenue from increased participation in the global trials market and developing tools that support service reviews through ongoing monitoring

• Supporting academic research by developing tools to support text-mining to create real knowledge from distributed and heterogeneous data

Cristal Health will use any profits generated to re-invest into its core purpose of accelerating improvements in medical research, services and outcomes for patients with a mental illness and/or dementia.

To find out more about Cristal Health contact: CEO, Mike Denis, Mike@cristalhealth.co.uk or CIO David, Newton, David@cristalhealth.co.uk.

 

 

Similar stories

Updating the circuit maps of the sympathetic neural network

A new review from Professor Ana Domingos’ lab and colleagues offers a fresh modern viewpoint on sympathetic neurons and their relation to immune cells and obesity.

Many adolescents game a lot without negative effects on their wellbeing

Although many school-age adolescents are spending considerable time gaming, it is not having a negative impact on their wellbeing.

Few mental health apps make it to real world, according to new Oxford University study

Despite enthusiasm for digital technology in addressing young people’s mental health, few effective apps have been successfully rolled out.

Study reveals association between diagnosis of a neuropsychiatric condition and severe outcome from COVID-19 infection, and other severe acute respiratory infections

New research from the University of Oxford has shown an increased risk of severe illness and death from both COVID-19 and other severe respiratory infections, such as influenza and pneumonia, among people with a pre-existing mental health condition.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.